11 March 2002
Selected parameters of fibrinolysis system in patients with dermatitis herpetiformis.
Anna Wankiewicz, Izabela Iwan-Zietek, Maria Kotschy, Zenon GwieździńskiMed Sci Monit 2002; 8(3): CR189-192 :: ID: 420904
Abstract
BACKGROUND: Dermatitis herpetiformis (DH) is a very rare bullous dermatitisof autoimmune origin. It is a syndrome involving dermal and intestinal pathology, in which vesicopapularskin lesions are accompanied by gluten-dependent enteropathy. The diagnosis of DH is based on immunopathologicalinvestigation of unaffected skin bioptate (presence of granular IgA deposits in the upper portions ofdermal papillae). MATERIAL/METHODS: The study was carried out in a group of 33 patients, including 23males and 10 females aged 22-78 (mean age 44.7 years). The following fibrinolysis system parameters weredetermined in the sera of all patients: tissue plasminogen activator concentration (t-PA: Ag), urokinaseplasminogen activator concentration (u-PA: Ag), plasminogen activator inhibitor concentration (PAI-Ag),plasminogen level, alpha-2 antiplasmin activity (alpha-2-AP), plasmin-- alpha-2 antiplasmin complexesconcentration (PAP). RESULTS: Mean t-PA concentration in DH patients was 5.52 ng/ml, vs. 4.8 ng/ml incontrols. The respective u-PA concentrations amounted to 0.33 ng/ml, and 0.39 ng/ml. PAI-1 concentrationwas markedly higher in DH patients (36.2 ng/ml) than in controls (22.40 ng/ml), whereas plasminogen levelwas significantly lower (86.0% vs. 115.9%). In patients, alpha-2-AP activity was 92% and was lower thanin controls -103.4%. DH patients demonstrated also higher concentrations of PAP complexes (327.45 ng/ml)than the control group (203.03 ng/ml). CONCLUSIONS: Patients with DH were found to have lower plasminogenand alpha-2 antiplasmin levels and increased concentrations of PAP complexes, which indicates increasedplasminogenesis in vivo. Increased type 1 plasminogen activator inhibitor level (PAI-1) may reflect achronic inflammatory condition present in DH patients.
Keywords: Antiplasmin, Autoimmune Diseases, dermatitis herpetiformis, Fibrinolysis, Immunoglobulin A, Plasminogen, Plasminogen Inactivators, Sex Factors, Tissue Plasminogen Activator, Urinary Plasminogen Activator
Editorial
01 February 2025 : Editorial
Editorial: Current Approaches to Screening for Lung Cancer in Smokers and Non-SmokersDOI: 10.12659/MSM.948255
Med Sci Monit 2025; 31:e948255
In Press
Clinical Research
Surgical Efficacy in Varicocele Ligation with Ephedrine-Assisted Blood Pressure ControlMed Sci Monit In Press; DOI: 10.12659/MSM.946234
Clinical Research
Retrospective Study to Compare Injury Patterns and Associations in 170 Patients Following Electric Scooter ...Med Sci Monit In Press; DOI: 10.12659/MSM.947155
Review article
Hydrogels in Oral Disease Management: A Review of Innovations in Drug Delivery and Tissue RegenerationMed Sci Monit In Press; DOI: 10.12659/MSM.946122
Clinical Research
Procedure Dynamics in Transfemoral vs Transradial Cerebral Angiography: A Retrospective StudyMed Sci Monit In Press; DOI: 10.12659/MSM.947603
Most Viewed Current Articles
17 Jan 2024 : Review article 6,968,724
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 701,829
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 25,567
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 20,099
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912